Irina Kulikovskaya
A5011478481- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Viral Infectious Diseases and Gene Expression in Insects
- Biosimilars and Bioanalytical Methods
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Cardiomyopathy and Myosin Studies
- Virus-based gene therapy research
- T-cell and B-cell Immunology
- Multiple Myeloma Research and Treatments
- CRISPR and Genetic Engineering
- Monoclonal and Polyclonal Antibodies Research
- Cardiovascular Effects of Exercise
- Insect Resistance and Genetics
- Advancements in Semiconductor Devices and Circuit Design
- Nanowire Synthesis and Applications
- Cancer Cells and Metastasis
- Muscle Physiology and Disorders
- Biomedical Ethics and Regulation
- Signaling Pathways in Disease
- Viral Infections and Immunology Research
- Integrated Circuits and Semiconductor Failure Analysis
- Neuroblastoma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
University of Pennsylvania
2016-2025
Southern Federal University
2023
Northwestern University
2005
Thomas Jefferson University
1998-2000
Sidney Kimmel Cancer Center
1998
Oxford Brookes University
1995
CRISPR-Cas9 gene editing provides a powerful tool to enhance the natural ability of human T cells fight cancer. We report first-in-human phase 1 clinical trial test safety and feasibility multiplex engineer in three patients with refractory Two genes encoding endogenous cell receptor (TCR) chains, TCRα (
T cells engineered to express affinity-enhanced TCRs directed a MAGE A3 peptide cross-react with similar, but unrelated, self-peptide.
Chimeric antigen receptors (CAR) are synthetic molecules that provide new specificities to T cells. Although successful in treatment of hematologic malignancies, CAR cells ineffective for solid tumors date. We found the cell-surface molecule c-Met was expressed ∼50% breast tumors, prompting construction a cell specific c-Met, which halted tumor growth immune-incompetent mice with xenografts. then evaluated safety and feasibility treating metastatic cancer intratumoral administration...
BACKGROUND. Multiple myeloma is usually fatal due to serial relapses that become progressively refractory therapy. CD19 typically absent on the dominant multiple cell population but may be present minor subsets with unique myeloma-propagating properties. To target cells, we clinically evaluated autologous T cells transduced a chimeric antigen receptor (CAR) against (CTL019).
Purpose: Treatments are limited for metastatic melanoma and triple-negative breast cancer (mTNBC). This pilot phase I trial (NCT03060356) examined the safety feasibility of intravenous RNA-electroporated chimeric antigen receptor (CAR) T cells targeting cell-surface cMET. Experimental Design: Metastatic or mTNBC subjects had at least 30% tumor expression cMET, measurable disease progression on prior therapy. Patients received up to six infusions (1 × 10e8 cells/dose) CAR without...
HIV is adept at avoiding naturally generated T cell responses; therefore, there a need to develop HIV-specific cells with greater potency for use in cure strategies. Starting CD4-based chimeric antigen receptor (CAR) that was previously used without toxicity clinical trials, we optimized the vector backbone, promoter, targeting moiety, and transmembrane signaling domains determine which components augmented ability of control replication. This re-engineered CAR least 50-fold more potent...
Replication-competent retrovirus/lentivirus (RCR/L) and insertional oncogenesis are potential safety risks with integrating viruses in gene-modified cell therapies. As such, the Food Drug Administration guidances outline RCR/L-monitoring methods throughout entire gene therapy treatment cycle. We present data for 17 vector lots, 375 manufactured T products, 308 patients post-infusion across both HIV oncology indications, showing no evidence of RCR/L. Given our data, a Poisson probability...
Chimeric antigen receptor (CAR) T cells have induced remarkable antitumor responses in B cell malignancies. Some patients do not respond because of deficiencies that hamper the expansion, persistence, and effector function these cells. We used longitudinal immune profiling to identify phenotypic pharmacodynamic changes CD19-directed CAR with chronic lymphocytic leukemia (CLL). expression maintenance was also investigated this can affect response durability. failure accompanied by preexisting...
Abstract We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR (huCART19) in multiple myeloma (MM) patients responding to third- later-line therapy (phase A, N = 10) high-risk first-line B, 20), followed by early lenalidomide pomalidomide maintenance. observed no high-grade cytokine release syndrome (CRS) and only one instance low-grade neurologic toxicity. Among 15 subjects measurable disease, 10 exhibited partial...
In contrast to skeletal muscle isoforms of myosin binding protein C (MyBP-C), the cardiac isoform has 11 rather than 10 fibronectin or Ig modules (modules are identified as C0 C10, NH2 COOH terminus), 3 phosphorylation sites between C1 and C2, 28 additional amino acids rich in proline C5. Phosphorylation C2 increases maximum Ca-activated force (Fmax), alters thick filament structure, probability heads on actin thin filament. Unphosphorylated C1C2 fragment binds myosin, but inhibits binding....
The involvement of neutrophil activation in the sentinel, potentially reversible, events pathogenesis acute lung injury (ALI) is only partially understood. alpha-Defensins are most abundant proteins secreted by activated human neutrophils, but their contribution to ALI mouse models hindered absence from murine neutrophils and inability study effects isolation other species.To role alpha-defensins a clinically relevant setting using mice transgenic for polymorphonuclear leukocyte expression...